Literature DB >> 7030234

Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases.

R Ebringer, G Rook, G T Swana, G F Bottazzo, D Doniach.   

Abstract

Cartilage antibodies were demonstrated by indirect immunofluorescence (IFL) on human fetal cartilage in 6 out of 9 patients with relapsing polychondritis (RPC), in 4 out of 260 patients with rheumatoid arthritis (RA), and in only 1 out of 1016 patients with other disorders. The antibodies were specific for cartilage and evenly stained the whole cartilage matrix. They were predominantly of IgG class and varied in titres from 1:1 to 1:320. Follow-up studies in the RPC patients indicated that higher titres were present during the early acute phase of the disease. Five of the 6 positive cases had developed the disease within the past 12 months, and the 3 negative cases had had the disease for 3 to 7 years when tested. The RA cases showing positive cartilage IFL had no clinical evidence of RPC. Sequential measurements in 2 of the 4 cases showed that these antibodies became detectable some years after the onset of arthritis. Absorption studies with human type II collagen and purified porcine proteoglycan failed to remove the cartilage IFL. Antibodies to human native type II collagen were measured by an enzyme-linked immunosorbent assay. The highest levels were found in the RA sera which also displayed cartilage IFL, but the 2 tests gave discordant results. RPC sera showed the same antibody levels by this method, as did cartilage-IFL-negative RA sera, though both groups had higher mean levels than health controls. The findings that cartilage antibodies are detected in the majority of cases of RPC and only rarely in other diseases suggests these antibodies may play an important role in the pathogenesis of cartilage destruction in RPC.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030234      PMCID: PMC1000784          DOI: 10.1136/ard.40.5.473

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Early rheumatoid disease. I. Onset.

Authors:  A Fleming; J M Crown; M Corbett
Journal:  Ann Rheum Dis       Date:  1976-08       Impact factor: 19.103

2.  Relapsing polychondritis with insulin resistance and antibodies to cartilage.

Authors:  P H Rogers; G Boden; C D Tourtellotte
Journal:  Am J Med       Date:  1973-08       Impact factor: 4.965

3.  Relapsing polychondritis. Analytical literature review and studies on pathogenesis.

Authors:  D L Dolan; G B Lemmon; S L Teitelbaum
Journal:  Am J Med       Date:  1966-08       Impact factor: 4.965

4.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

5.  Cell-mediated immunity to cartilage proteoglycan in relapsing polychondritis.

Authors:  D A Rajapakse; E G Bywaters
Journal:  Clin Exp Immunol       Date:  1974-03       Impact factor: 4.330

Review 6.  Relapsing polychondritis: prospective study of 23 patients and a review of the literature.

Authors:  L P McAdam; M A O'Hanlan; R Bluestone; C M Pearson
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

7.  Relapsing polychondritis. Electron microscopic study of ear cartilage.

Authors:  S R Shaul; H R Schumacher
Journal:  Arthritis Rheum       Date:  1975 Nov-Dec

8.  Antibodies to native and denatured collagens in sera of patients with rheumatoid arthritis.

Authors:  N A Andriopoulos; J Mestecky; E J Miller; E L Bradley
Journal:  Arthritis Rheum       Date:  1976 May-Jun

9.  Immunopathologic studies in relapsing polychondritis.

Authors:  J H Herman; M V Dennis
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

10.  Anomalous reactions in the haemagglutination assay for anti-collagen antibodies: studies on patients with rheumatoid arthritis or chronic low back pain.

Authors:  H K Beard; D J Lea; R Ryvar
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

View more
  29 in total

1.  Disastrous Complication Caused Indirectly by the Success of Battlefield Acupuncture.

Authors:  Daniel G Federman
Journal:  Med Acupunct       Date:  2020-06-16

2.  Corneal autoimmunity in a patient with relapsing polychondritis.

Authors:  F W Albers; M H Majoor; R Van der Gaag
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

3.  Pneumatosis cystoides intestinalis in relapsing polychondritis.

Authors:  Seung-Ki Kwok; Soo-Hong Seo; Hyun-Sook Kim; Ji Hyeon Ju; Chong-Hyeon Yoon; Sung-Hwan Park; Ho-Youn Kim
Journal:  Clin Rheumatol       Date:  2006-10-18       Impact factor: 2.980

Review 4.  What do anti-collagen antibodies mean?

Authors:  K Morgan
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

Review 5.  Relapsing polychondritis: a chameleon among orphan diseases.

Authors:  Sabine Schumacher; Herwig Pieringer
Journal:  Wien Med Wochenschr       Date:  2017-03-31

6.  Extra-articular cartilage affected in collagen-induced, but not pristane-induced, arthritis models.

Authors:  A-S Hansson; S Lu; R Holmdahl
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

7.  Use of expandable metal stents in the treatment of bronchial obstruction.

Authors:  A K Simonds; J D Irving; S W Clarke; R Dick
Journal:  Thorax       Date:  1989-08       Impact factor: 9.139

8.  Tracheal stenosis due to relapsing polychondritis in rheumatoid arthritis.

Authors:  M E Rogerson; E M Higgins; R C Godfrey
Journal:  Thorax       Date:  1987-11       Impact factor: 9.139

9.  Progressive tracheobronchial polychondritis: need for early diagnosis.

Authors:  J B Neilly; J H Winter; R D Stevenson
Journal:  Thorax       Date:  1985-01       Impact factor: 9.139

10.  Myelodysplastic syndrome associated with relapsing polychondritis: unusual transformation from refractory anemia to chronic myelomonocytic leukemia.

Authors:  T Shirota; O Hayashi; H Uchida; N Tonozuka; N Sakai; H Itoh
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.